These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 39089309)
1. Evaluating the KEYNOTE-057 trial's findings: addressing demographic, methodological, and economic considerations. Wang S Lancet Oncol; 2024 Aug; 25(8):e335. PubMed ID: 39089309 [No Abstract] [Full Text] [Related]
2. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods. Chen MH; Willan AR Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520 [TBL] [Abstract][Full Text] [Related]
4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials. Hlatky MA Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595 [No Abstract] [Full Text] [Related]
5. Rationale and design of the SMaRT trial: A randomised, prospective, parallel, non-blinded, one-centre trial to evaluate the use of magnetic resonance imaging in acute setting in patients presenting with suspected scaphoid fracture. Rua T; Vijayanathan S; Parkin D; Goh V; McCrone P; Gidwani S Clin Trials; 2018 Apr; 15(2):120-129. PubMed ID: 29366329 [TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis conducted alongside randomized controlled trials: are economic end points considered in sample size calculations and does it matter? Hollingworth W; McKell-Redwood D; Hampson L; Metcalfe C Clin Trials; 2013 Feb; 10(1):43-53. PubMed ID: 23231969 [TBL] [Abstract][Full Text] [Related]
7. Cheap research is likely to be biased. White A; Hart A Complement Ther Med; 2002 Jun; 10(2):59-60. PubMed ID: 12481952 [No Abstract] [Full Text] [Related]
8. Factors to consider when designing phase III clinical trials involving economic evaluations. van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753 [TBL] [Abstract][Full Text] [Related]
13. The cost-benefit of a randomized trial to a health care organization. Hornberger J; Eghtesady P Control Clin Trials; 1998 Apr; 19(2):198-211. PubMed ID: 9551284 [TBL] [Abstract][Full Text] [Related]
14. Cluster trials in implementation research: estimation of intracluster correlation coefficients and sample size. Campbell MK; Mollison J; Grimshaw JM Stat Med; 2001 Feb; 20(3):391-9. PubMed ID: 11180309 [TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of a worksite obesity prevention and intervention trial among hotel workers in Hawaii. Meenan RT; Vogt TM; Williams AE; Stevens VJ; Albright CL; Nigg C J Occup Environ Med; 2010 Jan; 52 Suppl 1(Suppl 1):S8-13. PubMed ID: 20061889 [TBL] [Abstract][Full Text] [Related]
18. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169 [TBL] [Abstract][Full Text] [Related]
19. [Application of pragmatic randomized controlled trial's design in clinical research of acupuncture]. Shi GX; Liu CZ; Wang LP Zhongguo Zhong Xi Yi Jie He Za Zhi; 2010 Feb; 30(2):193-6. PubMed ID: 20462051 [TBL] [Abstract][Full Text] [Related]
20. Health services research clinical trials: issues in the evaluation of economic costs and benefits. Manheim LM Control Clin Trials; 1998 Apr; 19(2):149-58. PubMed ID: 9551279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]